Stem cells as vectors for antitumour therapy.

Stem cells and cell therapies in lung biology and lung diseases. Proc Am Thorac Soc (2011) 1.66

Concise review: current status of stem cells and regenerative medicine in lung biology and diseases. Stem Cells (2014) 1.21

Stem cells and regenerative medicine in lung biology and diseases. Mol Ther (2012) 1.08

Mesenchymal stem cells at the intersection of cell and gene therapy. Expert Opin Biol Ther (2010) 1.07

Biological characteristics of stem cells from foetal, cord blood and extraembryonic tissues. J R Soc Interface (2010) 1.06

Tissue-derived mesenchymal stromal cells used as vehicles for anti-tumor therapy exert different in vivo effects on migration capacity and tumor growth. BMC Med (2013) 0.92

Bortezomib sensitizes non-small cell lung cancer to mesenchymal stromal cell-delivered inducible caspase-9-mediated cytotoxicity. Cancer Gene Ther (2014) 0.90

Systemic but not topical TRAIL-expressing mesenchymal stem cells reduce tumour growth in malignant mesothelioma. Thorax (2014) 0.88

Stem cells, cell therapies, and bioengineering in lung biology and diseases. Comprehensive review of the recent literature 2010-2012. Ann Am Thorac Soc (2013) 0.88

The challenge of pancreatic cancer therapy and novel treatment strategy using engineered mesenchymal stem cells. Cancer Gene Ther (2014) 0.86

Mesenchymal stem cell-mediated cancer therapy: A dual-targeted strategy of personalized medicine. World J Stem Cells (2011) 0.86

Stem cells' guided gene therapy of cancer: New frontier in personalized and targeted therapy. J Cancer Res Ther (Manch) (2014) 0.85

Potential of Mesenchymal Stem Cell based application in Cancer. Int J Hematol Oncol Stem Cell Res (2015) 0.85

Amniotic membrane-derived cells inhibit proliferation of cancer cell lines by inducing cell cycle arrest. J Cell Mol Med (2012) 0.84

Keratinocyte growth factor gene delivery via mesenchymal stem cells protects against lipopolysaccharide-induced acute lung injury in mice. PLoS One (2013) 0.82

Cancer cell-oriented migration of mesenchymal stem cells engineered with an anticancer gene (PTEN): an imaging demonstration. Onco Targets Ther (2014) 0.82

Exosomes and Their Therapeutic Potentials of Stem Cells. Stem Cells Int (2015) 0.81

Influence of mesenchymal stem cells on metastasis development in mice in vivo. Stem Cell Res Ther (2015) 0.81

Stem cells and cell therapies in lung biology and diseases: conference report. Ann Am Thorac Soc (2013) 0.80

Melanoma cell therapy: Endothelial progenitor cells as shuttle of the MMP12 uPAR-degrading enzyme. Oncotarget (2014) 0.79

Mesenchymal stem cell: a new horizon in cancer gene therapy. Cancer Gene Ther (2016) 0.78

In vivo near-infrared imaging for the tracking of systemically delivered mesenchymal stem cells: tropism for brain tumors and biodistribution. Int J Nanomedicine (2015) 0.78

Umbilical Cord Tissue-Derived Cells as Therapeutic Agents. Stem Cells Int (2015) 0.78

Exogenous marker-engineered mesenchymal stem cells detect cancer and metastases in a simple blood assay. Stem Cell Res Ther (2015) 0.76

PTEN-mRNA engineered mesenchymal stem cell-mediated cytotoxic effects on U251 glioma cells. Oncol Lett (2016) 0.76

Mesenchymal stem cells as a novel vaccine platform. Front Cell Infect Microbiol (2012) 0.76

Adipose‑derived mesenchymal stem cell‑facilitated TRAIL expression in melanoma treatment in vitro. Mol Med Rep (2016) 0.75

The application of mRNA-based gene transfer in mesenchymal stem cell-mediated cytotoxicity of glioma cells. Oncotarget (2016) 0.75

Cancer statistics, 2007. CA Cancer J Clin (2007) 53.49

Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy (2006) 37.55

Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell (2005) 18.20

Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med (1986) 17.64

Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature (2007) 15.20

Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet (2008) 12.59

Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med (2006) 11.66

Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity (1995) 10.59

Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells (2007) 8.64

Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J Clin Invest (2004) 7.91

Immune cell migration in inflammation: present and future therapeutic targets. Nat Immunol (2005) 7.47

Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc Natl Acad Sci U S A (2003) 7.41

Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. N Engl J Med (2006) 7.28

Transcoronary transplantation of progenitor cells after myocardial infarction. N Engl J Med (2006) 6.77

Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem (1996) 6.22

Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone. Proc Natl Acad Sci U S A (2002) 6.05

Gastric cancer originating from bone marrow-derived cells. Science (2004) 6.04

Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst (2004) 5.39

Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res (2005) 5.17

Human mesenchymal stem cells modulate B-cell functions. Blood (2005) 5.12

Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res (2002) 4.99

Retracted Spontaneous human adult stem cell transformation. Cancer Res (2005) 4.95

Mesenchymal stem cell homing: the devil is in the details. Cell Stem Cell (2009) 4.75

Bone marrow-derived mesenchymal stem cells in repair of the injured lung. Am J Respir Cell Mol Biol (2005) 4.57

Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood (2003) 4.43

The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer (2008) 4.42

Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood (2004) 4.03

Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J Clin Oncol (2000) 3.94

From the laboratory bench to the patient's bedside: an update on clinical trials with mesenchymal stem cells. J Cell Physiol (2007) 3.87

Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma. J Exp Med (2006) 3.81

The in vitro migration capacity of human bone marrow mesenchymal stem cells: comparison of chemokine and growth factor chemotactic activities. Stem Cells (2007) 3.68

Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood (2006) 3.52

Human bone marrow derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms. Cancer Res (2007) 3.19

Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene Ther (2004) 2.97

Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat Rev Drug Discov (2008) 2.95

Bone marrow contribution to tumor-associated myofibroblasts and fibroblasts. Cancer Res (2004) 2.86

Human bone marrow stromal cells express a distinct set of biologically functional chemokine receptors. Stem Cells (2005) 2.80

Review: Biological relevance of disseminated tumor cells in cancer patients. Int J Cancer (2008) 2.72

Mesenchymal stem cells: paradoxes of passaging. Exp Hematol (2004) 2.52

Inflammation and tumor microenvironments: defining the migratory itinerary of mesenchymal stem cells. Gene Ther (2008) 2.50

Mesenchymal stem cells display coordinated rolling and adhesion behavior on endothelial cells. Blood (2006) 2.49

Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy. Proc Natl Acad Sci U S A (2009) 2.47

Primary murine MSC show highly efficient homing to the bone marrow but lose homing ability following culture. Leukemia (2003) 2.39

Bone marrow mesenchymal stem cells express a restricted set of functionally active chemokine receptors capable of promoting migration to pancreatic islets. Blood (2005) 2.39

Prevention of lung reperfusion injury in rabbits by a monoclonal antibody against interleukin-8. Nature (1993) 2.38

Targeted migration of mesenchymal stem cells modified with CXCR4 gene to infarcted myocardium improves cardiac performance. Mol Ther (2008) 2.25

Adipose tissue-derived human mesenchymal stem cells mediated prodrug cancer gene therapy. Cancer Res (2007) 2.18

Interactions of chemokines and chemokine receptors mediate the migration of mesenchymal stem cells to the impaired site in the brain after hypoglossal nerve injury. Stem Cells (2004) 2.12

Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer. Cancer Res (2009) 2.09

Mesenchymal stem cells derived from bone marrow favor tumor cell growth in vivo. Exp Mol Pathol (2005) 2.07

The growth inhibitory effect of mesenchymal stem cells on tumor cells in vitro and in vivo. Cancer Biol Ther (2007) 2.05

Mesenchymal stem cells inhibit proliferation and apoptosis of tumor cells: impact on in vivo tumor growth. Leukemia (2006) 2.04

Tumor irradiation increases the recruitment of circulating mesenchymal stem cells into the tumor microenvironment. Cancer Res (2007) 2.03

Bone-marrow-derived myofibroblasts contribute to the cancer-induced stromal reaction. Biochem Biophys Res Commun (2003) 2.00

Interleukin-6 is a potent growth factor for ER-alpha-positive human breast cancer. FASEB J (2007) 1.99

Stem cells and cell therapies in lung biology and lung diseases. Proc Am Thorac Soc (2008) 1.98

Monocyte chemotactic protein-1 secreted by primary breast tumors stimulates migration of mesenchymal stem cells. Clin Cancer Res (2007) 1.97

Gene therapy using TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma. Cancer Res (2008) 1.88

Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses. Mol Cancer Ther (2006) 1.88

Towards in situ tissue repair: human mesenchymal stem cells express chemokine receptors CXCR1, CXCR2 and CCR2, and migrate upon stimulation with CXCL8 but not CCL2. J Cell Biochem (2007) 1.86

Mesenchymal stem cells as cellular immunosuppressants. Lancet (2008) 1.85

Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle. Transplantation (2007) 1.83

Mesenchymal stem cells use integrin beta1 not CXC chemokine receptor 4 for myocardial migration and engraftment. Mol Biol Cell (2007) 1.72

Hypoxia promotes murine bone-marrow-derived stromal cell migration and tube formation. Stem Cells (2003) 1.70

Outgrowth of a transformed cell population derived from normal human BM mesenchymal stem cell culture. Cytotherapy (2005) 1.70

Dkk-1 secreted by mesenchymal stem cells inhibits growth of breast cancer cells via depression of Wnt signalling. Cancer Lett (2008) 1.68

Role of the SDF-1/CXCR4 axis in the pathogenesis of lung injury and fibrosis. Am J Respir Cell Mol Biol (2007) 1.61

Murine but not human mesenchymal stem cells generate osteosarcoma-like lesions in the lung. Stem Cells (2007) 1.59

Differential gene expression associated with migration of mesenchymal stem cells to conditioned medium from tumor cells or bone marrow cells. Stem Cells (2006) 1.56

Comprehensive analysis of chemotactic factors for bone marrow mesenchymal stem cells. Stem Cells Dev (2007) 1.49

A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies. Clin Cancer Res (2008) 1.44

Migration of culture-expanded human mesenchymal stem cells through bone marrow endothelium is regulated by matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-3. Haematologica (2007) 1.44

Cancer gene therapy using mesenchymal stem cells expressing interferon-beta in a mouse prostate cancer lung metastasis model. Gene Ther (2008) 1.42

Mesenchymal stem cells as a vehicle for targeted delivery of CRAds to lung metastases of breast carcinoma. Breast Cancer Res Treat (2007) 1.41

Therapeutic potential of mesenchymal stem cells producing interferon-alpha in a mouse melanoma lung metastasis model. Stem Cells (2008) 1.38

Targeted delivery of CX3CL1 to multiple lung tumors by mesenchymal stem cells. Stem Cells (2007) 1.35

Human fetal mesenchymal stem cells as vehicles for gene delivery. Stem Cells (2005) 1.34

High-efficiency transduction and long-term gene expression with a murine stem cell retroviral vector encoding the green fluorescent protein in human marrow stromal cells. Hum Gene Ther (1999) 1.33

Cytosine deaminase expressing human mesenchymal stem cells mediated tumour regression in melanoma bearing mice. J Gene Med (2008) 1.31

Earlier onset of syngeneic tumors in the presence of mesenchymal stem cells. Transplantation (2006) 1.29

Targeted delivery of NK4 to multiple lung tumors by bone marrow-derived mesenchymal stem cells. Cancer Gene Ther (2007) 1.27

Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer. Lung Cancer (2008) 1.27

Therapeutic potential of mesenchymal stromal cells in a mouse breast cancer metastasis model. Cytotherapy (2009) 1.26

Human adult CD34- progenitor cells functionally express the chemokine receptors CCR1, CCR4, CCR7, CXCR5, and CCR10 but not CXCR4. Stem Cells Dev (2005) 1.22

Human mesenchymal stem cells lack tumor tropism but enhance the antitumor activity of oncolytic adenoviruses in orthotopic lung and breast tumors. Hum Gene Ther (2007) 1.19

Efficient lentiviral transduction and improved engraftment of human bone marrow mesenchymal cells. Stem Cells (2005) 1.18

Human mesenchymal stem cells maintain transgene expression during expansion and differentiation. Mol Ther (2001) 1.17

Effects of sequential treatments with chemotherapeutic drugs followed by TRAIL on prostate cancer in vitro and in vivo. Prostate (2005) 1.16

Ionizing radiation enhances the therapeutic potential of TRAIL in prostate cancer in vitro and in vivo: Intracellular mechanisms. Prostate (2004) 1.16

Factor(s) from nonmacrophage bone marrow stromal cells inhibit Lewis lung carcinoma and B16 melanoma growth in mice. Cell Mol Life Sci (1999) 1.13

Bid mediates apoptotic synergy between tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and DNA damage. J Biol Chem (2004) 1.11

Cardiac regeneration and stem cell therapy. Curr Opin Organ Transplant (2008) 1.11

Retroviral vector-producing mesenchymal stem cells for targeted suicide cancer gene therapy. J Gene Med (2009) 1.10

Bone marrow contributes to epithelial cancers in mice and humans as developmental mimicry. Stem Cells (2007) 1.10

Mesenchymal stem cells and inflammatory lung diseases. Panminerva Med (2009) 1.09

A tumor-selective biotherapy with prolonged impact on established metastases based on cytokine gene-engineered MSCs. Mol Ther (2008) 1.09

Prophylaxis against carcinogenesis in three kinds of unestablished tumor models via IL12-gene-engineered MSCs. Carcinogenesis (2006) 1.07

Doxorubicin increases the effectiveness of Apo2L/TRAIL for tumor growth inhibition of prostate cancer xenografts. BMC Cancer (2005) 1.04

Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin. Mol Cancer (2007) 1.02

NF-kappaB downregulation may be involved the depression of tumor cell proliferation mediated by human mesenchymal stem cells. Acta Pharmacol Sin (2008) 0.99

Suitability of endobronchial ultrasound-guided transbronchial needle aspiration specimens for subtyping and genotyping of non-small cell lung cancer: a multicenter study of 774 patients. Am J Respir Crit Care Med (2012) 5.21

Endobronchial ultrasound-guided transbronchial needle aspiration prevents mediastinoscopies in the diagnosis of isolated mediastinal lymphadenopathy: a prospective trial. Am J Respir Crit Care Med (2012) 3.01

Utility of endobronchial ultrasound-guided transbronchial needle aspiration in patients with tuberculous intrathoracic lymphadenopathy: a multicentre study. Thorax (2011) 2.60

Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer. Cancer Res (2009) 2.09

Tumor heterogeneity and permeability as measured on the CT component of PET/CT predict survival in patients with non-small cell lung cancer. Clin Cancer Res (2013) 2.08

Lung cancer and lung stem cells: strange bedfellows? Am J Respir Crit Care Med (2006) 1.79

Murine but not human mesenchymal stem cells generate osteosarcoma-like lesions in the lung. Stem Cells (2007) 1.59

Membrane-spanning DNA nanopores with cytotoxic effect. Angew Chem Int Ed Engl (2014) 1.58

Mediastinal staging of NSCLC with endoscopic and endobronchial ultrasound. Nat Rev Clin Oncol (2009) 1.46

Esophageal endoscopic ultrasound/endobronchial ultrasound-guided fine needle aspiration: a new dawn for the respiratory physician? Am J Respir Crit Care Med (2007) 1.44

Magnetic resonance imaging of mesenchymal stem cells homing to pulmonary metastases using biocompatible magnetic nanoparticles. Cancer Res (2009) 1.42

The learning curve for EBUS-TBNA. Thorax (2010) 1.41

Combination of endobronchial ultrasound-guided transbronchial needle aspiration with standard bronchoscopic techniques for the diagnosis of stage I and stage II pulmonary sarcoidosis. Respirology (2011) 1.32

Endobronchial ultrasound-guided transbronchial needle aspiration for the diagnosis of intrathoracic lymphadenopathy in patients with extrathoracic malignancy: a multicenter study. J Thorac Oncol (2011) 1.23

Bone marrow stem cells expressing keratinocyte growth factor via an inducible lentivirus protects against bleomycin-induced pulmonary fibrosis. PLoS One (2009) 1.15

Stochastic homeostasis in human airway epithelium is achieved by neutral competition of basal cell progenitors. Elife (2013) 1.15

Lung cancer: progress in diagnosis, staging and therapy. Respirology (2010) 1.14

Therapeutic potential of stem cells in lung disease: progress and pitfalls. Clin Sci (Lond) (2008) 1.03

Stem cells of the alveolar epithelium. Lancet (2005) 1.02

Mesenchymal stem cells as vectors for lung disease. Proc Am Thorac Soc (2008) 0.99

A general mechanism for intracellular toxicity of metal-containing nanoparticles. Nanoscale (2014) 0.98

Stem cells for lung disease. Chest (2007) 0.97

LRIG1 regulates cadherin-dependent contact inhibition directing epithelial homeostasis and pre-invasive squamous cell carcinoma development. J Pathol (2013) 0.92

β-Catenin determines upper airway progenitor cell fate and preinvasive squamous lung cancer progression by modulating epithelial-mesenchymal transition. J Pathol (2012) 0.92

Stem cells and pulmonary fibrosis: cause or cure? Proc Am Thorac Soc (2012) 0.91

Stem Cell Implants for Cancer Therapy: TRAIL-Expressing Mesenchymal Stem Cells Target Cancer Cells In Situ. J Breast Cancer (2012) 0.88

Myd88 deficiency influences murine tracheal epithelial metaplasia and submucosal gland abundance. J Pathol (2011) 0.85

Mesenchymal stem cells as vectors for lung cancer therapy. Respiration (2013) 0.85

Integrated 18F-fluorodeoxyglucose-positron emission tomography/dynamic contrast-enhanced computed tomography to phenotype non-small cell lung carcinoma. Mol Imaging (2012) 0.82

Thoracic Oncology HERMES syllabus: setting the basis for thoracic oncology training in Europe. Eur Respir J (2013) 0.81

Tissue engineering airway mucosa: a systematic review. Laryngoscope (2013) 0.80

High prevalence of malignancy in HIV-positive patients with mediastinal lymphadenopathy: a study in the era of antiretroviral therapy. Respirology (2014) 0.80

Genomic evidence of pre-invasive clonal expansion, dispersal and progression in bronchial dysplasia. J Pathol (2011) 0.78

Rac1 deletion causes thymic atrophy. PLoS One (2011) 0.76

Pulmonary mass in a 19-year-old male. Inflammatory myofibroblastic tumour. Thorax (2011) 0.75

Reply: endobronchial ultrasound–guided transbronchial needle aspiration versus cervical mediastinoscopy: case selection is needed to maintain clinical as well as cost benefits. Am J Respir Crit Care Med (2013) 0.75

Reply: Optimum performance of endobronchial ultrasound-guided transbronchial needle aspiration. Am J Respir Crit Care Med (2013) 0.75

Endobronchial ultrasound-guided transbronchial needle aspiration for lymphoma: the final frontier. Am J Respir Crit Care Med (2013) 0.75

EBUS-TBNA for the mediastinal staging of non-small cell lung cancer. J Thorac Oncol (2009) 0.75

Lung cancer staging with minimally invasive endoscopic techniques. JAMA (2008) 0.75

Primed infusion with delayed equilibrium of Gd.DTPA for enhanced imaging of small pulmonary metastases. PLoS One (2013) 0.75

Reply: lung cancer diagnosis and staging centers. Am J Respir Crit Care Med (2013) 0.75

Mesenchymal stem cell therapy for lung diseases: oasis or mirage? Respiration (2013) 0.75